Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?

Amaral-Machado, Lucas; Oliveira, Wógenes N.; Rodrigues, Victor Muniz; Albuquerque, Nathan A.; Alencar, Éverton do Nascimento; Egito, Eryvaldo Sócrates Tabosa do

doi:10.1016/j.biopha.2020.111143

Cited by 15 publications

(6 citation statements)

References 99 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported that the use of anakinra, a dual blocker of IL-1α and IL-1β, in COVID-19 patients reduced the mortality risk, especially in the presence of signs of hyperin ammation [6, [32][33][34]. However, facing the severity of COVID-19, it is imperative to identify treatments that are easily accessible to the population who do not need to be hospitalized [35]. In this scenario, CINNA, as an easy-to-assume nutraceutical, represents a promising preventive approach to be used to prevent the appearance or aggravation of COVID-19 respiratory symptoms.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumonia.

Vezzani,

Perrone,

Carinci

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: The recent pandemic outbursts, due to SARS-CoV-2, has highlighted once more the central role of the inflammatory process in the propagation of viral infection. In fact, the main consequence of COVID-19 is the induction of a diffuse pro-inflammatory state, also defined as cytokine storm, that affects different organs, but mostly the lungs. Therefore, despite the progress in the vaccination campaign, the high mutability of this virus also requires effective pharmaceutical approaches aimed to reduce the inflammatory spread. Methods The effect of SARS-CoV-2 infection on IL-1β and IL-6 levels was assessed by performing ELISA on patients' serum and stimulated-PBMCs. The therapeutic potential of cinnamaldehyde on COVID-19 was evaluated in vitro, testing the effects on THP-1 macrophages' inflammatory state, and on the viral replication in Calu-3 and Vero6 cells. Moreover, we assessed the effect of cinnamaldehyde also in vivo generating a lung-inflammatory model by intranasal administration of LPS. Results In this study we highlight that COVID-19 patients have higher IL-1β and IL-6 plasma levels compared to non-COVID-19 pneumonia patients, showing that human mononuclear cells (PBMCs) isolated from SARS-CoV-2 infected patients are more prone to release pro-inflammatory cytokines upon stimuli. Furthermore, we demonstrated how cinnamaldehyde, a natural compound easily tolerated by the majority of human beings, significantly reduces SARS-CoV-2-related inflammation by inhibiting IL-1β release by macrophages, and viral replication in epithelial cells. In addition, we confirmed the ability of aerosol-administered cinnamaldehyde to in vivo reduce IL-1β release in a lung-inflammatory model. Conclusion The obtained results suggest the possible use of cinnamaldehyde suitable as a co-adjuvant preventive treatment for COVID-19 disease together with vaccination, but also as a promising dietary supplement to reduce, more broadly, viral induced inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumonia.

Vezzani,

Perrone,

Carinci

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Several pharmaceutical active natural products (PANPs) have shown anti-inflammatory effects and lung protection against ARDS in animal models. For example, in previous studies, omentin and vaspin mitigated inflammatory response in mice with ARDS induced by lipopolysaccharide (LPS), berberine inhibited NF-κB pathway activation, and tetrahydroberberine was associated with a decrease in inflammatory mediators' levels like TNFα (21).…”

Section: Other Agents With Possible Anti-inflammatory Effectsmentioning

confidence: 96%

“…Following the extensive cellular damage after becoming infected with the virus, dead cell debris can elicit a macrophage-dependent inflammatory response (20). Endothelial cells are also contributed to the pulmonary damage process as they facilitate the cumulating and extravasation of neutrophils and leukocytes (21). Accordingly, macrophages of the alveolar tissue express ACE2 and can become directly infected by the virus (20,22) (Figure 1).…”

Section: Current Knowledge About Sars-cov-2 Pathogenesismentioning

confidence: 99%

Prospective approach to manage COVID-19-related cytokine storm; an updated review on current concepts

Bahmani¹,

Saberian²

2021

J Prev Epidemiol

View full text Add to dashboard Cite

Coronavirus disease 2019 or COVID-19, caused by the novel human coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019, in the city of Wuhan, Hubei province, China. Unfortunately, despite many efforts to find cures for SARS-CoV-2 disease, still the management of severe cases remains challenging. In severe forms of COVID-19, proinflammatory cytokines are notably elevated (3) and reminiscent of the secondary hemophagocytic lymphohistiocytosis (HLH). According to many studies, immune imbalance and an uncontrolled massive release of inflammatory cytokines have a significant role in COVID-19 severity and ARDS pathophysiology. Accordingly, targeting the over-activated immune system to prevent tissue damage is now one of the most noticed possible strategies to manage severe COVID-19 cases. In the present study, we reviewed studies and clinical trials conducted in this regard.

show abstract

“…Recent research suggests that lung inflammation and airway damage contribute to morbidity and mortality due to SARS –CoV-2 ( Amaral-Machado et al., 2020 ). The mortality in COVID-19 occurs due to the extreme release of cytokines, leading to the inflammation of lung tissue ( Long et al., 2020 ; Terpos et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective

Rahman

Islam

Akash

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a substantial number of deaths around the world, making it a serious and pressing public health hazard. Phytochemicals could thus provide a rich source of potent and safer anti-SARS-CoV-2 drugs. The absence of approved treatments or vaccinations continues to be an issue, forcing the creation of new medicines. Computer-aided drug design has helped to speed up the drug research and development process by decreasing costs and time. Natural compounds like terpenoids, alkaloids, polyphenols, and flavonoid derivatives have a perfect impact against viral replication and facilitate future studies in novel drug discovery. This would be more effective if collaboration took place between governments, researchers, clinicians, and traditional medicine practitioners’ safe and effective therapeutic research. Through a computational approach, this study aims to contribute to the development of effective treatment methods by examining the mechanisms relating to the binding and subsequent inhibition of SARS-CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). The in silico method has also been employed to determine the most effective drug among the mentioned compound and their aquatic, nonaquatic, and pharmacokinetics’ data have been analyzed. The highest binding energy has been reported -11.4 kcal/mol against SARS-CoV-2 main protease (7MBG) in L05. Besides, all the ligands are non-carcinogenic, excluding L04, and have good water solubility and no AMES toxicity. The discovery of preclinical drug candidate molecules and the structural elucidation of pharmacological therapeutic targets have expedited both structure-based and ligand-based drug design. This review article will assist physicians and researchers in realizing the enormous potential of computer-aided drug design in the design and discovery of therapeutic molecules, and hence in the treatment of deadly diseases.

show abstract

Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?

Cited by 15 publications

References 99 publications

SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumonia.

SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumonia.

Prospective approach to manage COVID-19-related cytokine storm; an updated review on current concepts

In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective

Contact Info

Product

Resources

About